Multiple Myeloma
Conditions
Interventions
Lenalidomide 15mg/day days1-21, prednisone 15mg/day three times a week, in a 28-day cycle
Sponsors
Nara Hospital Kinki University School Of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: .Multiple myeloma patient who is over 70 years old .Agree to register and follow RevMate .In the patients receiving the notice, fully briefed for the consent document and other documents given explanation about the contents of the study physician or study investigator, agreed in writing to voluntarily participate in the study by have been obtained
Exclusion criteria
Exclusion criteria: .Cardiac infarction within 6 months .Deep vein thrombosis or pulmonary embolism within 3 years .Tuberculosis, herpes simplex keratitis, mycosis, or other active infections at baseline .Uncontrollable diabetes mellitus, hypertension, peptic ulcer, or glaucoma .Posterior capsule opacification .Patients with mental illness .Those who are considered as inappropriate to register by attending physicians .Pregnant or breast feeding females .Known hypersensitivity to prednisone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of adverse events Duration of response Progression-free survival Overall survival | — |
Countries
Japan
Contacts
Public Contacthitoshi hanamoto
Nara Hospital Kinki University School Of Medicine Department of Hematology
Outcome results
None listed